EXEL

Exelixis
D

EXEL

58.320
USD
-0.18
(-0.31%)
Post Trading·58.760USD+0.440(+0.75%)
حجم التداول
68,047
الربح لكل سهم
3
العائد الربحي
-
P/E
18
حجم السوق
14,450,628,277
أصول ذات صلة المقالات
المزيد

العنوان: Exelixis

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.